Moderna's chairman, Noubar Afeyan, says the company won't share the recipe for its COVID-19 vaccine because scaling up its own production is the best way to increase the global supply. The U.N. health agency has pressed Moderna to share its formula.
Moderna co-founder and chairman Noubar Afeyan listens to questions during an interview with the Associated Press, in Rome, Monday, Oct. 11, 2021.
In an interview with The Associated Press, Noubar Afeyan also reiterated a pledge Moderna made a year ago not to enforce patent infringement on anyone else making a coronavirus vaccine during the pandemic.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Covid-19: NHS Covid passes, and lockdown lifted in SydneyFive things you need to know about the coronavirus pandemic this Monday morning.
続きを読む »
Covid-19: Three more Covid-related deaths and 1,115 new casesThe total number of coronavirus-linked deaths in NI since the start of the pandemic is 2,588.
続きを読む »
Primero COVID-19, ahora VIH: Científicos de Moderna y San Diego trabajan para crear una vacunaLos investigadores planean utilizar una serie de inyecciones para enseñar al sistema inmunitario a producir respuestas de anticuerpos contra el virus
続きを読む »
Tension eases in Rome after Covid-19 vaccine rule protest – latest updatesCovid19 has infected more than 238.3M people and killed over 4.8M globally. Here are the latest updates: 🇮🇹 Tension eases in Rome after Covid-19 vaccine rule protest 🇲🇽 Mexico reports 6,153 new cases 🇧🇷 Brazil reports 404 new deaths For more:
続きを読む »
U.S. administers nearly 402 million COVID-19 vaccine doses, CDC saysThose figures are up from the 400,669,422 vaccine doses the CDC said had been administered by Friday out of 485,713,525 doses delivered. The CDC tally includes the two-dose vaccines from Moderna and Pfizer/BioNTech, as well as Johnson & Johnson's one-shot vaccine. Roughly 7.8 million people have received a booster dose of either Pfizer or Moderna's vaccine since Aug. 13, when the United States authorized a third dose of the vaccines for people with compromised immune systems who are likely to have weaker protection from the two-dose regimens.
続きを読む »